ClinicalTrials.gg
CompletedNCT05366738Updated Mar 29, 2024Results posted

A Study to Determine the Bioavailability of Vonoprazan Sprinkle Capsules on Pudding or on Applesauce Relative to a Vonoprazan Tablet in Healthy Participants

A Phase 1 interventional study of Vonoprazan and Vonoprazan in Healthy Volunteers, sponsored by Phathom Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-29.

Sponsored by Phathom Pharmaceuticals, Inc. · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing vonoprazan in Gastroesophageal Reflux — 5 open to participants now, 5 under way, 1 of them phase 3. vonoprazan · Gastroesophageal Reflux.

Enrollment
13th of 16
27 · median 118
Started
2022
with 1 other
Phase 1
5 of 16
none open now
Registered
8th of 16
by date
Lead sponsor
4 of 16
Phathom Pharmaceuticals, Inc.

Among the 16 studies testing vonoprazan in Gastroesophageal Reflux, this one is the 13th largest by enrollment, is one of 2 that started in 2022, is one of 5 in phase 1, and was the 8th registered.

Gastroesophageal Reflux

1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

5 of the 16 studies testing vonoprazan in Gastroesophageal Reflux are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About vonoprazan

vonoprazan: first FDA approval 2022 (VOQUEZNA TRIPLE PAK). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing vonoprazan in Gastroesophageal Reflux, or all of them as a file.
02

Study summary

The primary objective of this study is to assess the bioavailability (BA) of a single oral dose of vonoprazan 20 mg sprinkle capsule, either sprinkled on pudding or on applesauce, relative to a vonoprazan 20 mg tablet in healthy participants.

Read the detailed description

This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).

03

Conditions studied

  • Healthy Volunteers

Keywords

  • Vonoprazan
  • Gastroesophageal Reflux
  • Erosive Esophagitis
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant is male or female 18 to 55 years of age, inclusive, at Screening.
  • The participant has a 18 to 32 kg/m\^2, inclusive, at Screening.
  • The participant is considered by the investigator to be in good general health as determined by medical history, clinical laboratory test results, vital sign measurements, 12-lead results, and physical examination findings at Screening.
  • Male and female participants of must use an acceptable method of (i.e., diaphragm with spermicide, intrauterine device, condom with foam or vaginal spermicide, oral contraceptives, or abstinence) from the signing of until 4 weeks after the last dose of study drug or be surgically sterile (i.e., vasectomy, hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or (defined as amenorrhea for 12 consecutive months and documented plasma follicle stimulating hormone [FSH] level >40 international unit (IU)/mL during Screening).
  • Female participants must have a negative pregnancy test at Screening and upon Check-in.
  • The participant agrees to comply with all protocol requirements.
  • The participant is able to provide written informed consent.

Exclusion criteria

Exclusion Criteria:

  • The participant has a positive test result for surface antigen, virus antibody, or types 1 or 2 antibodies at Screening.
  • The participant has a positive test result for the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at Screening or Check-in.
  • The participant has a history of a neurological, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, or endocrine disease or other abnormality that may impact the ability of the participant to participate.
  • The participant has current or recent (within 6 months) gastrointestinal conditions that would be expected to influence the absorption of drugs (e.g., history of malabsorption, esophageal reflux, peptic ulcer disease, erosive esophagitis [EE]), frequent (more than once per week) occurrence of heartburn, or any surgical intervention.
  • The participant has any other clinically significant findings on physical examination, clinical laboratory abnormalities, and/or results that preclude his/her participation in the study, as deemed by the investigator.
  • The participant has used any prescription (excluding hormonal ) and/or over-the-counter medications (including inducers) except acetaminophen (up to 2 g per day), including herbal or nutritional supplements, within 14 days before the first dose of study drug, and/or is expected to require any such medication during the course of the study until end of treatment period phase (ET) or end of study (EOS).
  • The participant has consumed grapefruit and/or grapefruit juice, Seville orange or Seville orange-containing products (eg, marmalade), or other food products that may be CYP3A4 inhibitors (eg, vegetables from the mustard green family [kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, mustard] and charbroiled meats) within 7 days (or 5 half-lives) before the first dose of study drug and/or is expected to be unable to abstain through the study.
  • The participant has consumed caffeine- or xanthine-containing products within 48 hours (or 5 half-lives) before the first dose of study drug and/or is unable to abstain through the study.
  • The participant is a smoker and/or has used nicotine or nicotine-containing products (eg, snuff, nicotine patch, nicotine chewing gum, mock cigarettes, or inhalers) within 6 months before the first dose of study drug.
  • The participant has a history of alcohol abuse and/or drug addiction within the last year or excessive alcohol consumption (regular alcohol intake >21 units per week for male participants and >14 units of alcohol per week for female participants; 1 unit is equal to approximately 1/2 pint [200 mL] of beer, 1 small glass [100 mL] of wine, or 1 measure [25 mL] of spirits) or use of alcohol 48 hours before the first dose of study drug.
  • The participant has a positive test result for drugs of abuse, alcohol, or cotinine (indicating active current smoking) at Screening or Check-in.
  • The participant is involved in strenuous activity or contact sports within 24 hours before the first dose of study drug and during the study.
  • The participant has donated blood or blood products >450 mL within 30 days before the first dose of study drug.
  • The participant has a history of relevant drug and/or food allergies (i.e., allergy to vonoprazan or or any significant food allergy that could preclude a standard diet in the clinical unit).
  • The participant has received a study drug in another study within 30 days of dosing.
  • Female participants who are pregnant or lactating; intend to become pregnant before, during, or within 4 weeks after participating in this study; or intend to donate ova during this time period.
  • The participant is not suitable for entry into the study in the opinion of the investigator.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Treatment Sequence 1

    Participants assigned to Treatment Sequence 1 will receive vonoprazan 20 mg as a sprinkle capsule on 1 tablespoon of pudding on Day 1 of Treatment Period 1, vonoprazan 20 mg as a sprinkle capsule on 1 tablespoon of applesauce on Day 1 of Treatment Period 2, and vonoprazan 20 mg as a tablet on Day 1 of Treatment Period 3.

    Drug: Vonoprazan

  • Experimental
    Treatment Sequence 2

    Participants assigned to Treatment Sequence 2 will receive vonoprazan 20 mg as a tablet on Day 1 of Treatment Period 1, vonoprazan 20 mg as a sprinkle capsule on 1 tablespoon of pudding on Day 1 of Treatment Period 2, and vonoprazan 20 mg as a sprinkle capsule on 1 tablespoon of applesauce on Day 1 of Treatment Period 3.

    Drug: Vonoprazan

  • Experimental
    Treatment Sequence 3

    Participants assigned to Treatment Sequence 3 will receive vonoprazan 20 mg as a sprinkle capsule on 1 tablespoon of applesauce on Day 1 of Treatment Period 1, vonoprazan 20 mg as a tablet on Day 1 of Treatment Period 2, and vonoprazan 20 mg as a sprinkle capsule on 1 tablespoon of pudding on Day 1 of Treatment Period 3.

    Drug: Vonoprazan

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration (AUC0-t) of Vonoprazan

    Time frame: Day 1 of each 3-day Treatment Period: Within 0.25 hours pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose.

  2. Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Vonoprazan

    Time frame: Day 1 of each 3-day Treatment Period: Within 0.25 hours pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose.

  3. Maximum Observed Plasma Concentration (Cmax) of Vonoprazan

    Time frame: Day 1 of each 3-day Treatment Period: Within 0.25 hours pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose.

Secondary outcomes

  1. Time to Maximum Observed Plasma Concentration (Tmax) of Vonoprazan

    Time frame: Day 1 of each 3-day Treatment Period: Within 0.25 hours pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose.

  2. Terminal Phase Half-life (t1/2) of Vonoprazan

    Time frame: Day 1 of each 3-day Treatment Period: Within 0.25 hours pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose.

  3. Apparent Total Body Clearance (CL/F) of Vonoprazan

    Time frame: Day 1 of each 3-day Treatment Period: Within 0.25 hours pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose.

  4. Apparent Volume of Distribution (Vz/F) of Vonoprazan

    Time frame: Day 1 of each 3-day Treatment Period: Within 0.25 hours pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose.

  5. Terminal Elimination Rate Constant (λz) of Vonoprazan

    Time frame: Day 1 of each 3-day Treatment Period: Within 0.25 hours pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose.

07

Results

Posted Mar 29, 2024

Participant flow

27 participants were randomized in a 1:1:1 ratio to 1 of 3 treatment sequences at 1 site in the United States.

Participant flow — Overall Study
MilestoneVonoprazan 20 mg: Treatment Sequence 1Vonoprazan 20 mg: Treatment Sequence 2Vonoprazan 20 mg: Treatment Sequence 3
Started999
Completed treatment a (vonoprazan 20 mg sprinkle capsule on pudding)989
Completed treatment b (vonoprazan 20 mg sprinkle capsule on applesauce)989
Completed treatment c (vonoprazan 20 mg tablet)999
Completed989
Not completed010
Withdrew: Adverse event010

Outcome measures

PrimaryArea Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration (AUC0-t) of Vonoprazan
Time frame:
Day 1 of each 3-day Treatment Period: Within 0.25 hours pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose.
Reported as:
Geometric mean · ng•h/mL
Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration (AUC0-t) of Vonoprazan
ng•h/mLTreatment A: Vonoprazan 20 mg Sprinkle Capsule on PuddingTreatment B: Vonoprazan 20 mg Sprinkle Capsule on ApplesauceTreatment C: Vonoprazan 20 mg Tablet
Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration (AUC0-t) of Vonoprazan228 ± 44.9216 ± 46.0219 ± 47.3
Statistical analysis
  • Treatment A: Vonoprazan 20 mg Sprinkle Capsule on Pudding vs Treatment C: Vonoprazan 20 mg Tablet · Ratio of geometric least square means: 103.36 · 90% CI 97.64 to 109.41
  • Treatment B: Vonoprazan 20 mg Sprinkle Capsule on Applesauce vs Treatment C: Vonoprazan 20 mg Tablet · Ratio of geometric least square means: 97.83 · 90% CI 92.42 to 103.56
PrimaryArea Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Vonoprazan
Time frame:
Day 1 of each 3-day Treatment Period: Within 0.25 hours pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose.
Reported as:
Geometric mean · ng•h/mL
Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Vonoprazan
ng•h/mLTreatment A: Vonoprazan 20 mg Sprinkle Capsule on PuddingTreatment B: Vonoprazan 20 mg Sprinkle Capsule on ApplesauceTreatment C: Vonoprazan 20 mg Tablet
Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Vonoprazan238 ± 43.2227 ± 43.1231 ± 44.4
Statistical analysis
  • Treatment A: Vonoprazan 20 mg Sprinkle Capsule on Pudding vs Treatment C: Vonoprazan 20 mg Tablet · Ratio of geometric least square means: 102.56 · 90% CI 97.25 to 108.15
  • Treatment B: Vonoprazan 20 mg Sprinkle Capsule on Applesauce vs Treatment C: Vonoprazan 20 mg Tablet · Ratio of geometric least square means: 97.61 · 90% CI 92.55 to 102.93
PrimaryMaximum Observed Plasma Concentration (Cmax) of Vonoprazan
Time frame:
Day 1 of each 3-day Treatment Period: Within 0.25 hours pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose.
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Vonoprazan
ng/mLTreatment A: Vonoprazan 20 mg Sprinkle Capsule on PuddingTreatment B: Vonoprazan 20 mg Sprinkle Capsule on ApplesauceTreatment C: Vonoprazan 20 mg Tablet
Maximum Observed Plasma Concentration (Cmax) of Vonoprazan23.1 ± 44.222.4 ± 41.922.3 ± 45.3
Statistical analysis
  • Treatment A: Vonoprazan 20 mg Sprinkle Capsule on Pudding vs Treatment C: Vonoprazan 20 mg Tablet · Ratio of geometric least square means: 103.96 · 90% CI 96.49 to 112.00
  • Treatment B: Vonoprazan 20 mg Sprinkle Capsule on Applesauce vs Treatment C: Vonoprazan 20 mg Tablet · Ratio of geometric least square means: 100.60 · 90% CI 93.38 to 108.39
SecondaryTime to Maximum Observed Plasma Concentration (Tmax) of Vonoprazan
Time frame:
Day 1 of each 3-day Treatment Period: Within 0.25 hours pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose.
Reported as:
Median · hours
Time to Maximum Observed Plasma Concentration (Tmax) of Vonoprazan
hoursTreatment A: Vonoprazan 20 mg Sprinkle Capsule on PuddingTreatment B: Vonoprazan 20 mg Sprinkle Capsule on ApplesauceTreatment C: Vonoprazan 20 mg Tablet
Time to Maximum Observed Plasma Concentration (Tmax) of Vonoprazan2.00 (1.50 to 6.00)2.01 (1.00 to 6.00)2.00 (1.50 to 6.02)
SecondaryTerminal Phase Half-life (t1/2) of Vonoprazan
Time frame:
Day 1 of each 3-day Treatment Period: Within 0.25 hours pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose.
Reported as:
Geometric mean · hours
Terminal Phase Half-life (t1/2) of Vonoprazan
hoursTreatment A: Vonoprazan 20 mg Sprinkle Capsule on PuddingTreatment B: Vonoprazan 20 mg Sprinkle Capsule on ApplesauceTreatment C: Vonoprazan 20 mg Tablet
Terminal Phase Half-life (t1/2) of Vonoprazan7.50 ± 19.57.20 ± 18.47.29 ± 16.0
SecondaryApparent Total Body Clearance (CL/F) of Vonoprazan
Time frame:
Day 1 of each 3-day Treatment Period: Within 0.25 hours pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose.
Reported as:
Geometric mean · litres/h
Apparent Total Body Clearance (CL/F) of Vonoprazan
litres/hTreatment A: Vonoprazan 20 mg Sprinkle Capsule on PuddingTreatment B: Vonoprazan 20 mg Sprinkle Capsule on ApplesauceTreatment C: Vonoprazan 20 mg Tablet
Apparent Total Body Clearance (CL/F) of Vonoprazan83.9 ± 43.288.1 ± 43.186.6 ± 44.4
SecondaryApparent Volume of Distribution (Vz/F) of Vonoprazan
Time frame:
Day 1 of each 3-day Treatment Period: Within 0.25 hours pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose.
Reported as:
Geometric mean · litres
Apparent Volume of Distribution (Vz/F) of Vonoprazan
litresTreatment A: Vonoprazan 20 mg Sprinkle Capsule on PuddingTreatment B: Vonoprazan 20 mg Sprinkle Capsule on ApplesauceTreatment C: Vonoprazan 20 mg Tablet
Apparent Volume of Distribution (Vz/F) of Vonoprazan908 ± 37.6915 ± 33.4911 ± 38.5
SecondaryTerminal Elimination Rate Constant (λz) of Vonoprazan
Time frame:
Day 1 of each 3-day Treatment Period: Within 0.25 hours pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose.
Reported as:
Geometric mean · 1/h
Terminal Elimination Rate Constant (λz) of Vonoprazan
1/hTreatment A: Vonoprazan 20 mg Sprinkle Capsule on PuddingTreatment B: Vonoprazan 20 mg Sprinkle Capsule on ApplesauceTreatment C: Vonoprazan 20 mg Tablet
Terminal Elimination Rate Constant (λz) of Vonoprazan0.0924 ± 19.50.0963 ± 18.40.0951 ± 16.0

Adverse events

Collected over Day 1 to Day 31. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A: Vonoprazan 20 mg Sprinkle Capsule on Pudding0/26 (0%)0/26 (0%)2/26 (7.7%)
Treatment B: Vonoprazan 20 mg Sprinkle Capsule on Applesauce0/26 (0%)0/26 (0%)2/26 (7.7%)
Treatment C: Vonoprazan 20 mg Tablet0/27 (0%)0/27 (0%)4/27 (14.8%)
Most frequent other events
Most frequent other events
EventTreatment A: Vonoprazan 20 mg Sprinkle Capsule on PuddingTreatment B: Vonoprazan 20 mg Sprinkle Capsule on ApplesauceTreatment C: Vonoprazan 20 mg Tablet
HeadacheNervous system disorders0/262/260/27
Arthropod biteInjury, poisoning and procedural complications1/260/260/27
Skin lacerationInjury, poisoning and procedural complications1/260/260/27
Muscle contractions involuntaryNervous system disorders0/260/261/27
Abdominal discomfortGastrointestinal disorders0/260/261/27
Oral mucosal rougheningGastrointestinal disorders0/260/261/27
SARS-CoV-2 test positiveInvestigations0/260/261/27

Baseline characteristics

Age, Continuous
Age, Continuous(years)Vonoprazan 20 mg: Treatment Sequence 1Vonoprazan 20 mg: Treatment Sequence 2Vonoprazan 20 mg: Treatment Sequence 3Total
Mean35.1 ± 7.2232.9 ± 8.5135.8 ± 9.6334.6 ± 8.27
Sex: Female, Male
Sex: Female, Male(Participants)Vonoprazan 20 mg: Treatment Sequence 1Vonoprazan 20 mg: Treatment Sequence 2Vonoprazan 20 mg: Treatment Sequence 3Total
Female52411
Male47516
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Vonoprazan 20 mg: Treatment Sequence 1Vonoprazan 20 mg: Treatment Sequence 2Vonoprazan 20 mg: Treatment Sequence 3Total
Hispanic or Latino62311
Not Hispanic or Latino37616
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Vonoprazan 20 mg: Treatment Sequence 1Vonoprazan 20 mg: Treatment Sequence 2Vonoprazan 20 mg: Treatment Sequence 3Total
American Indian or Alaska Native0101
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American42410
White56516
More than one race0000
Unknown or Not Reported0000
08

Study locations

1 site
  • PPD Development, LP
    Austin, Texas 78744, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Jul 2022, 1 month.

Results were first posted in Mar 2024, 1 year 8 months after primary completion.

Of 28 industry-sponsored phase 1 interventional studies under Gastroesophageal Reflux, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 6. This study's 1 month is below that.

Counting every sponsor, half of 34 studies reached it within 4 months; a quarter within 2 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2022
First posted
May 9, 2022
StartActual
May 18, 2022
Primary completionActual
Jul 1, 2022
CompletionActual
Jul 26, 2022
Results first posted
Mar 29, 2024
Last update
Mar 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05366738
Lead sponsor
Phathom Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
May 9, 2022
Start date
May 18, 2022
Primary completion
Jul 1, 2022
Completion
Jul 26, 2022
Results posted
Mar 29, 2024
Last update
Mar 29, 2024

Study contacts

Medical Director
study director · Phathom Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vonoprazan

Start the discussion